王海旭,王悦喜

• 1:内蒙古医科大学附属医院心血管内科

摘要(Abstract)：

<正>我国冠心病的发病率逐年升高,且由于不合理的饮食结构、相对不足的运动锻炼以及各种心血管疾病危险因素使得冠心病的发病人群呈现年轻化趋势。随着冠心病发病率与住院率的不断上涨,我国的冠心病经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)手术量亦保持较高的年增长率~([1])。PCI患者增多使得心脏支架的使用也随之

关键词(KeyWords)： 支架内再狭窄;药物洗脱球囊;介入治疗

Abstract:

Keywords:

基金项目(Foundation): 内蒙古自治区蒙医药协同创新培育中心研究基金

作者(Author): 王海旭,王悦喜

参考文献(References)：

• [1]《药物涂层球囊临床应用中国专家共识》专家组.药物涂层球囊临床应用中国专家共识.中国介入心脏病学杂志,2016,24(2):61-67.
• [2]Lee M,Pessegueiro AR,Jurewitz D,et al.Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era.J Invasive Cardiol,2008,20(8):401-403.
• [3]Schnorr B,Speck U,Scheller B.Review of clinical data with Paccocath-coated balloon catheters.Minerva Cardioangiol,2011,59(5):431-445.
• [4]Taniwaki M,Stefanini GG,Silber S,et al.4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents:a report from the RESOLUTE All-Comers trial(A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting.J Am Coll Cardiol,2014,63(16):1617-1625.
• [5]Ialenti A,Grassia G,Gordon P,et al.Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries.Arterioscler Thromb Vasc Biol,2011,31(11):2448-2454.
• [6]Zhu Jb,Ge J.GW26-e1581 A meta-analysis of randomized controlled trials of plain old balloon angioplasty versus drugeluting balloon in patients with in-stent restenosis.J Am Coll Cardiol,2015,66(16):C232.
• [7]Lee ML.Cutting balloon angioplasty for in-stent restenosis of the aortic coarctation in a young boy presenting with systemic hypertension of the upper extremities.Acta Cardiologica,2013,68(6):639-641.
• [8]Kong J,Hou J,Ma L,et al.Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.Arch Cardiovasc Dis,2013,106(2):79-85.
• [9]Alfonso F,Pérez-Vizcayno MJ,García DBB,et al.Comparison of the efficacy of everolimus-eluting stents versus drug-eluting balloons in patients with in-stent restenosis(from the RIBS IV and V randomized clinical trials).Am J Cardiol,2016,117(4):546-554.
• [10]Alfonso F,Pérez-Vizcayno MJ,García DBB,et al.EverolimusEluting Stents in Patients With Bare-Metal and Drug-Eluting InStent Restenosis:Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.Circ Cardiovasc Interv,2016,9(7):e003479.
• [11]Yabe T,Toda M,Nakanishi R,et al.Same or different drugeluting stent re-implantation for drug-eluting stent restenosis:an assessment including second-generation drug-eluting stents.J Interv Cardiol,2016,29(3):311-318.
• [12]Moscarella E,Varricchio A,Stabile E,et al.Bioresorbable vascular scaffold implantation for the treatment of coronary instent restenosis:Results from a multicenter Italian experience.Int J Cardiol,2015,199(4):366-372.
• [13]Moscarella E,Ielasi A,Granata F,et al.Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis:A Multicenter Italian Experience.Circ Cardiovasc Interv,2016,9(4):366-372.
• [14]Ahmet K,Yasemin D.Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaffold in in-stent stenosis.Postepy Kardiol Interwencyjnej,2014,11(1):64-66.
• [15]Holmes Dr Jr,Teirstein PS,Satler L,et al.3-year follow-up of the SISR(sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis)trial.JACC Cardiovasc Interv,2008,1(4):439-448.
• [16]Negi SI,Torguson R,Gai J,et al.Intracoronary brachytherapy for recurrent drug-eluting stent failure.JACC Cardiovasc Interv,2016,9(12):1259-1265.
• [17]Lee KC,Dixon S,Wallace M,et al.Clinical outcomes in patients undergoing coronary brachytherapy with beta radiation after in-stent restenosis of a drug-eluting stent.Int J Radiat Oncol Biol Phys,2016,96(2S):E505.
• [18]Lu YG,Chen YM,Li L,et al.Drug-eluting stents vs intracoronary brachytherapy for in-stent restenosis:A Metaanalysis.Clin Cardiol,2011,34(6):344-351.
• [19]Abdel-Wahab M,Richardt G,Joachim Büttner H,et al.Highspeed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions:the randomized ROTAXUS(rotational atherectomy prior to taxus stent treatment for complex native coronary artery d Disease)trial.JACC Cardiovasc Interv,2012,6(1):10-19.
• [20]于一,赵迎新,史冬梅,等.准分子激光在经桡动脉复杂冠状动脉病变介入治疗中的应用.中国介入心脏病学杂志,2016,24(10):587-591.
• [21]Hirose S,Ashikaga T,Yu H,et al.Treatment of in-stent restenosis with excimer laser coronary angioplasty:benefits over scoring balloon angioplasty alone.Lasers Med Sci,2016,31(8):1691-1696.
• [22]Ambrosini V,Golino L,Niccoli G,et al.The combined use of drug-eluting balloon and excimer laser for coronary artery restenosis in-stent treatment:the DERIST study.Cardiovasc Revasc Med,2017,18(3):165-168.
• [23]Zavalloni D,Soldi M,Ferrante G,et al.Isolated left-anteriordescending artery in-stent restenosis:comparison between treatment with PCI-DES and CABG with left-internal-mammary artery.J Am Coll Cardiol,2013,62(18):B141.
• [24]Scheller B,Speck U,Abramjuk C,et al.Paclitaxel balloon coating,a novel method for prevention and therapy of restenosis.Circulation,2004,110(7):810-814.
• [25]Scheller B,Hehrlein C,Bocksch W,et al.Treatment of Coronary in-stent restenosis with a paclitaxel-coated balloon catheter.N Engl J Med,2006,355(20):2113-2124.
• [26]Scheller B,Clever Y P,Kelsch B,et al.Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxelcoated balloon catheter.JACC Cardiovasc Interv,2008,97(10):323-330.
• [27]Unverdorben M,Vallbracht C,Cremers B,et al.Paclitaxelcoated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis.Circulation,2009,119(23):2986-2994.
• [28]Rittger H,Brachmann J,Sinha AM,et al.A randomized,multicenter,single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study.J Am Coll Cardiol,2012,59(15):1377-1382.
• [29]Byrne R A,Neumann F J,Mehilli J,et al.Paclitaxel-eluting balloons,paclitaxel-eluting stents,and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE 3):a randomised,open-label trial.Lancet,2013,381(9865):461-467.
• [30]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [31]Xu B,Gao R,Wang J,et al.A prospective,multicenter,randomized trial of paclitaxel-coated balloon versus paclitaxeleluting stent for the treatment of drug-eluting stent in-stent restenosis:results from the PEPCAD China ISR trial.JACC Cardiovasc Interv,2014,7(2):204-211.